Bioorganic & Medicinal Chemistry 20 (2012) 6195–6197

Contents lists available at SciVerse ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc

Corrigendum

Corrigendum to 'Furin inhibitors: Importance of the positive formal charge and beyond' [*Bioorg. Med. Chem.* 20 (2012) 4462–4471]

Fabian López-Vallejo, Karina Martínez-Mayorga *

Torrey Pines Institute for Molecular Studies, 11350 SW Village Parkway, Port St. Lucie, FL 34987, USA

The authors regret that Table 4 appeared incorrectly. The corrected table appears below. Several references have also been corrected.

References and notes

7. (a) Henrich, S.; Cameron, A.; Bourenkov, G. P.; Kiefersauer, R.; Huber, R.; Lindberg, I.; Bode, W.; Than, M. E. *Nat. Struct. Biol.* **2003**, *10*, 669; (b) Henrich, S.; Cameron, A.; Bourenkov, G. P.; Kiefersauer, R.; Huber, R.; Lindberg, I.; Bode, W.; Than, M. E. *Nat. Struct. Biol.* **2003**, *10*, 520.
12. Cameron, A.; Appel, J.; Houghten, R. A.; Lindberg, I. *J. Biol. Chem.* **2000**, *275*, 36741.
19. Becker, G. L.; Sielaff, F.; Than, M. E.; Lindberg, I.; Routhier, S.; Day, R.; Lu, Y.; Garten, W.; Steinmetzer, T. *J. Med. Chem.* **2010**, *43*, 1067.
38. Apletalina, E.; Appel, J.; Lamango, N. S.; Houghten, R. A.; Lindberg, I. *J. Biol. Chem.* **1998**, *273*, 26589.
44. Jean, F.; Stella, K.; Thomas, L.; Liu, G.; Xiang, Y.; Reason, A. J.; Thomas, G. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 7293.

☆ DOI of original article: http://dx.doi.org/10.1016/j.bmc.2012.05.029
* Corresponding author. Tel.: +1 772 345 4688; fax: +1 772 345 3649.
E-mail address: kmartinez@tpims.org (K. Martínez-Mayorga).

0968-0896/$ - see front matter
http://dx.doi.org/10.1016/j.bmc.2012.08.027

Table 4
Structure of furin inhibitors used in docking sutudies

Compound	K_i (nM)	R	P4	P3	P2	P1	Refs.
1	3020	Phac	Arg	Val	Arg		
2	63	Phac	Arg	Val	Arg		
3	7490	Phac	Arg	Val	Arg		
4	78	Phac	Arg	Val	Arg		19
5	553	Phac	Arg	Val	Arg		
6	1070	Phac	Arg	Val	Arg		
7	627	Phac	Arg	Val	Arg		
8	1430	Phac	Arg	Val	Arg		
9	1320	Phac	Arg	Val	Arg		19
10	2730	Phac	Arg	Val	Arg		
11	9710	Phac	Arg	Val	Arg		
12	53	Phac	Arg	Val	Arg		19
13	0.81	Phac	Arg	Val	Arg		
14	1.6	Dec	Arg	Val	Arg		
15	1	Ac	Arg	Val	Arg		19
16	3.3	Dec	Arg	Val	Lys		
17	1400	Ac-Leu-Leu	Arg	Val	Lys	Arg-NH_2	38
18	1900	Ac-Leu-Met	Arg	Val	Lys	Arg-NH_2	

Table 4 (*continued*)

Compound	K_i (nM)	R	P4	P3	P2	P1	Refs.
19	190	Ac-Leu-Lys	Arg	Val	Lys	Arg-NH_2	
20	3400	Ac-Leu-Tyr	Arg	Val	Lys	Arg-NH_2	
21	800	H-Leu-Leu	Arg	Val	Lys	Arg-NH_2	12
22	3500	Ac-Leu-Leu	Arg	Val	Lys	Arg-OH	
23	420	H-Leu-Leu	Arg	Val	Lys	Arg-OH	
24	6400		H-Arg	Arg	Arg	Arg-OH	12
25	990	H-Arg	Arg	Arg	Arg	Arg-OH	
26	114	H-Arg-Arg	Arg	Arg	Arg	Arg-OH	
27	–	Dec	Arg	Val	Lys	Arg-CH_3	7,44

Molecule 27 resembles the co-crystallized ligand.